Biomarin Pharmaceutical INC Form 4 insider transactions

Charles Greg Guyer, EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., reports acquisition of stock options and restricted stock units, as well as disposition of shares to cover tax obligations.

Brian Mueller, EVP and CFO of BioMarin Pharmaceutical Inc., reports acquisition and disposal of common stock and stock options.

Henry J. Fuchs, President of Worldwide R&D at BioMarin Pharmaceutical Inc., reports acquisition and disposal of company stock and stock options.

BioMarin Pharmaceutical Inc. CEO Alexander Hardy reported the acquisition of 32,780 shares of common stock and 44,050 stock options on March 15, 2024.

Director Jean-Jacques Bienaime reports disposition of BioMarin Pharmaceutical stock to cover tax obligations.

Jeffrey Robert Ajer, EVP and Chief Commercial Officer of BioMarin Pharmaceutical Inc., disposed of 22,580 shares of common stock on March 15, 2024, to cover tax obligations.

Henry J. Fuchs, President of Worldwide R&D at BioMarin Pharmaceutical Inc., sold 35,341 shares of common stock at an average price of $85.1814 on March 5, 2024.

Director Jean-Jacques Bienaime of BioMarin Pharmaceutical Inc. reports selling 2,000 shares of common stock in early March 2024.

Jeffrey Robert Ajer, EVP and Chief Commercial Officer of BioMarin Pharmaceutical Inc., sold 4,000 shares of common stock at $87.07 per share on March 5, 2024, under a pre-arranged 10b5-1 trading plan.

Brian Mueller, EVP and CFO of BioMarin Pharmaceutical Inc., reports the acquisition of restricted stock units (RSUs) based on performance metrics from 2021-2023.

G. Eric Davis, EVP and Chief Legal Officer at BioMarin Pharmaceutical Inc., acquired restricted stock units (RSUs) based on the company's performance metrics between 2021 and 2023, as certified by the Board of Directors' Compensation Committee.

Charles Greg Guyer, EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., acquired shares of common stock through the vesting of Restricted Stock Units (RSUs) based on performance metrics.

Jeffrey Robert Ajer, EVP, Chief Commercial Officer of BioMarin Pharmaceutical Inc., acquired shares of common stock through the vesting of Restricted Stock Units (RSUs) on February 27, 2024.

Henry J. Fuchs, President of Worldwide R&D at BioMarin Pharmaceutical Inc., acquired shares of common stock through the vesting of Restricted Stock Units (RSUs) based on performance metrics.

Director Jean Jacques Bienaime reports acquisition of shares through Restricted Stock Units (RSUs) and disposal of shares via open market sale.